LEADER 02746nam 2200397z- 450 001 9910220047703321 005 20210212 035 $a(CKB)3800000000216300 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/57241 035 $a(oapen)doab57241 035 $a(EXLCZ)993800000000216300 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aProtein Interaction Networks in Health and Disease 210 $cFrontiers Media SA$d2016 215 $a1 online resource (89 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-982-7 330 $aThe identification and mapping of protein-protein interactions (PPIs) is a major goal in systems biology. Experimental data are currently produced in large scale using a variety of high-throughput assays in yeast or mammalian systems. Analysis of these data using computational tools leads to the construction of large protein interaction networks, which help researchers identify novel protein functions. However, our current view of protein interaction networks is still limited and there is an active field of research trying to further develop this concept to include important processes: the topology of interactions and their changes in real time, the effects of competition for binding to the same protein region, PPI variation due to alternative splicing or post-translational modifications, etc. In particular, a clinically relevant topic for development of the concept of protein interactions networks is the consideration of mutant isoforms, which may be responsible for a pathological condition. Mutations in proteins may result in loss of normal interactions and appearance of novel abnormal interactions that may affect a protein's function and biological cycle. This Research Topic presents novel findings and recent achievements in the field of protein interaction networks with a focus on disease. Authors describe methods for the identification and quantification of PPIs, the annotation and analysis of networks, considering PPIs and protein complexes formed by mutant proteins associated with pathological conditions or genetic diseases. 606 $aGenetics (non-medical)$2bicssc 610 $aDisease 610 $aProtein function 610 $aprotein interactions 610 $aprotein network 610 $aSystems Biology 615 7$aGenetics (non-medical) 700 $aMiguel A. Andrade-Navarro$4auth$01320409 702 $aSpyros Petrakis$4auth 906 $aBOOK 912 $a9910220047703321 996 $aProtein Interaction Networks in Health and Disease$93034273 997 $aUNINA LEADER 02546nam 2200445z- 450 001 9910166645703321 005 20210211 035 $a(CKB)3710000001092142 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/43398 035 $a(oapen)doab43398 035 $a(EXLCZ)993710000001092142 100 $a20202102d2016 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aClinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate 210 $cFrontiers Media SA$d2016 215 $a1 online resource (85 p.) 225 1 $aFrontiers Research Topics 311 08$a2-88919-846-4 330 $aStereotactic radiosurgery is a relatively recent radiation technique initially developed using a frame-based system in 1949 by a Swedish neurosurgeon, Lars Leksell, for lesions not amendable to surgical resection. Radiosurgery is founded on principles of extreme radiation dose escalation, afforded by precise dose delivery with millimeter accuracy. Building upon the success of frame-based radiosurgery techniques, which were limited to cranial tumors and invasive head-frame placement, advances in radiation delivery and image-guidance have lead to the development of stereotactic body radiotherapy (SBRT). SBRT allows for frameless delivery of dose distributions akin to frame-based cranial stereotactic radiosurgery to both cranial and extra-cranial sites and has emerged as a important treatment strategy for a variety of cancers from the cranium to prostate. Herein we highlight ongoing investigations for the clinical application of SBRT for a variety of primary and recurrence cancers aimed at examining the growing clinical evidence supporting emerging roles for SBRT in the ever growing oncologic armamentarium. 517 $aClinical Application of Stereotactic Body Radiotherapy 606 $aMedicine$2bicssc 610 $aAdrenal metastases 610 $aCentral Nervous System 610 $aGynecologic 610 $ahead and neck 610 $aNon small cell lung cancer 610 $aProstate 610 $astereotactic body radiation therapy 610 $aStereotactic radiosurgery 615 7$aMedicine 700 $aDwight E. Heron$4auth$01280035 702 $aJohn Austin Vargo$4auth 906 $aBOOK 912 $a9910166645703321 996 $aClinical Application of Stereotactic Body Radiotherapy (SBRT): Cranium to Prostate$93016371 997 $aUNINA